217 related articles for article (PubMed ID: 32764680)
1. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.
Au YZ; Gu M; De Braekeleer E; Gozdecka M; Aspris D; Tarumoto Y; Cooper J; Yu J; Ong SH; Chen X; Tzelepis K; Huntly BJP; Vassiliou G; Yusa K
Leukemia; 2021 Apr; 35(4):1012-1022. PubMed ID: 32764680
[TBL] [Abstract][Full Text] [Related]
2. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
3. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
4. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
[TBL] [Abstract][Full Text] [Related]
5. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
6. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
[TBL] [Abstract][Full Text] [Related]
7. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
8. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract][Full Text] [Related]
9. miR-101 suppresses the development of
Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
[No Abstract] [Full Text] [Related]
10. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
13. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
14. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
15. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
[TBL] [Abstract][Full Text] [Related]
16. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
17. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
18. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
19. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
20. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]